TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

A child who received the world's first personalized CRISPR therapy is now taking his first steps after months in hospital ...

Scientists are using CRISPR to fast-track the domestication of a wild fruit. For roughly 10,000 years, farming communities ...

CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.

A miracle baby who was treated with a pioneering gene-therapy at CHOP has reached a major milestone as he took his first ...

CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...